Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
麻豆原创 Analysis and Insights: Global Circulating Tumor Cell Diagnostics 麻豆原创
The global Circulating Tumor Cell Diagnostics market is projected to grow from US$ 5449.1 million in 2024 to US$ 9239.7 million by 2030, at a Compound Annual Growth Rate (CAGR) of 9.2% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Circulating Tumor Cell Diagnostics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Circulating Tumor Cell Diagnostics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Circulating Tumor Cell Diagnostics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Circulating Tumor Cell Diagnostics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Circulating Tumor Cell Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Circulating Tumor Cell Diagnostics revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
Segment by Type
CTC Enrichment
CTC Detection
CTC Analysis
Segment by Application
Tumorigenesis research
EMT biomarkers development
Cancer stem cell research
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Circulating Tumor Cell Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor Cell Diagnostics companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Circulating Tumor Cell Diagnostics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Circulating Tumor Cell Diagnostics 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 CTC Enrichment
1.2.3 CTC Detection
1.2.4 CTC Analysis
1.3 麻豆原创 by Application
1.3.1 Global Circulating Tumor Cell Diagnostics 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Tumorigenesis research
1.3.3 EMT biomarkers development
1.3.4 Cancer stem cell research
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor Cell Diagnostics 麻豆原创 Perspective (2019-2030)
2.2 Global Circulating Tumor Cell Diagnostics Growth Trends by Region
2.2.1 Circulating Tumor Cell Diagnostics 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Circulating Tumor Cell Diagnostics Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Circulating Tumor Cell Diagnostics Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Circulating Tumor Cell Diagnostics 麻豆原创 Dynamics
2.3.1 Circulating Tumor Cell Diagnostics Industry Trends
2.3.2 Circulating Tumor Cell Diagnostics 麻豆原创 Drivers
2.3.3 Circulating Tumor Cell Diagnostics 麻豆原创 Challenges
2.3.4 Circulating Tumor Cell Diagnostics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Circulating Tumor Cell Diagnostics by Players
3.1.1 Global Circulating Tumor Cell Diagnostics Revenue by Players (2019-2024)
3.1.2 Global Circulating Tumor Cell Diagnostics Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Circulating Tumor Cell Diagnostics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Circulating Tumor Cell Diagnostics, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Circulating Tumor Cell Diagnostics 麻豆原创 Concentration Ratio
3.4.1 Global Circulating Tumor Cell Diagnostics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cell Diagnostics Revenue in 2023
3.5 Global Key Players of Circulating Tumor Cell Diagnostics Head office and Area Served
3.6 Global Key Players of Circulating Tumor Cell Diagnostics, Product and Application
3.7 Global Key Players of Circulating Tumor Cell Diagnostics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumor Cell Diagnostics Breakdown Data by Type
4.1 Global Circulating Tumor Cell Diagnostics Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Circulating Tumor Cell Diagnostics Forecasted 麻豆原创 Size by Type (2025-2030)
5 Circulating Tumor Cell Diagnostics Breakdown Data by Application
5.1 Global Circulating Tumor Cell Diagnostics Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Circulating Tumor Cell Diagnostics Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size (2019-2030)
6.2 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type
6.2.1 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Circulating Tumor Cell Diagnostics 麻豆原创 Share by Type (2019-2030)
6.3 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application
6.3.1 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Circulating Tumor Cell Diagnostics 麻豆原创 Share by Application (2019-2030)
6.4 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country
6.4.1 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size (2019-2030)
7.2 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type
7.2.1 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Share by Type (2019-2030)
7.3 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application
7.3.1 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Share by Application (2019-2030)
7.4 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country
7.4.1 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Circulating Tumor Cell Diagnostics 麻豆原创 Size (2019-2030)
8.2 China Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type
8.2.1 China Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type (2019-2024)
8.2.2 China Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type (2025-2030)
8.2.3 China Circulating Tumor Cell Diagnostics 麻豆原创 Share by Type (2019-2030)
8.3 China Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application
8.3.1 China Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application (2019-2024)
8.3.2 China Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application (2025-2030)
8.3.3 China Circulating Tumor Cell Diagnostics 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Circulating Tumor Cell Diagnostics 麻豆原创 Size (2019-2030)
9.2 Asia Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type
9.2.1 Asia Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Circulating Tumor Cell Diagnostics 麻豆原创 Share by Type (2019-2030)
9.3 Asia Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application
9.3.1 Asia Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Circulating Tumor Cell Diagnostics 麻豆原创 Share by Application (2019-2030)
9.4 Asia Circulating Tumor Cell Diagnostics 麻豆原创 Size by Region
9.4.1 Asia Circulating Tumor Cell Diagnostics 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Circulating Tumor Cell Diagnostics 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Circulating Tumor Cell Diagnostics 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Janssen Diagnostics
11.1.1 Janssen Diagnostics Company Details
11.1.2 Janssen Diagnostics Business Overview
11.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Introduction
11.1.4 Janssen Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.1.5 Janssen Diagnostics Recent Developments
11.2 Advanced Cell Diagnostics
11.2.1 Advanced Cell Diagnostics Company Details
11.2.2 Advanced Cell Diagnostics Business Overview
11.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Introduction
11.2.4 Advanced Cell Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.2.5 Advanced Cell Diagnostics Recent Developments
11.3 Aviva Biosciences
11.3.1 Aviva Biosciences Company Details
11.3.2 Aviva Biosciences Business Overview
11.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Introduction
11.3.4 Aviva Biosciences Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.3.5 Aviva Biosciences Recent Developments
11.4 Biocept Inc
11.4.1 Biocept Inc Company Details
11.4.2 Biocept Inc Business Overview
11.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Introduction
11.4.4 Biocept Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.4.5 Biocept Inc Recent Developments
11.5 Biofluidica Inc.
11.5.1 Biofluidica Inc. Company Details
11.5.2 Biofluidica Inc. Business Overview
11.5.3 Biofluidica Inc. Circulating Tumor Cell Diagnostics Introduction
11.5.4 Biofluidica Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.5.5 Biofluidica Inc. Recent Developments
11.6 CellTraffix Inc.
11.6.1 CellTraffix Inc. Company Details
11.6.2 CellTraffix Inc. Business Overview
11.6.3 CellTraffix Inc. Circulating Tumor Cell Diagnostics Introduction
11.6.4 CellTraffix Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.6.5 CellTraffix Inc. Recent Developments
11.7 Clearbridge BioMedics Pte Ltd
11.7.1 Clearbridge BioMedics Pte Ltd Company Details
11.7.2 Clearbridge BioMedics Pte Ltd Business Overview
11.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Introduction
11.7.4 Clearbridge BioMedics Pte Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.7.5 Clearbridge BioMedics Pte Ltd Recent Developments
11.8 Epic Sciences Inc.
11.8.1 Epic Sciences Inc. Company Details
11.8.2 Epic Sciences Inc. Business Overview
11.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Introduction
11.8.4 Epic Sciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.8.5 Epic Sciences Inc. Recent Developments
11.9 Fluxion Biosciences Inc.
11.9.1 Fluxion Biosciences Inc. Company Details
11.9.2 Fluxion Biosciences Inc. Business Overview
11.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Introduction
11.9.4 Fluxion Biosciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.9.5 Fluxion Biosciences Inc. Recent Developments
11.10 ScreenCell
11.10.1 ScreenCell Company Details
11.10.2 ScreenCell Business Overview
11.10.3 ScreenCell Circulating Tumor Cell Diagnostics Introduction
11.10.4 ScreenCell Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.10.5 ScreenCell Recent Developments
11.11 Silicon Biosystems
11.11.1 Silicon Biosystems Company Details
11.11.2 Silicon Biosystems Business Overview
11.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Introduction
11.11.4 Silicon Biosystems Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.11.5 Silicon Biosystems Recent Developments
11.12 Sysmex Corporation
11.12.1 Sysmex Corporation Company Details
11.12.2 Sysmex Corporation Business Overview
11.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Introduction
11.12.4 Sysmex Corporation Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.12.5 Sysmex Corporation Recent Developments
11.13 Greiner Bio-One GmbH
11.13.1 Greiner Bio-One GmbH Company Details
11.13.2 Greiner Bio-One GmbH Business Overview
11.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Introduction
11.13.4 Greiner Bio-One GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.13.5 Greiner Bio-One GmbH Recent Developments
11.14 AdnaGen AG
11.14.1 AdnaGen AG Company Details
11.14.2 AdnaGen AG Business Overview
11.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Introduction
11.14.4 AdnaGen AG Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.14.5 AdnaGen AG Recent Developments
11.15 Apocell Inc
11.15.1 Apocell Inc Company Details
11.15.2 Apocell Inc Business Overview
11.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Introduction
11.15.4 Apocell Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.15.5 Apocell Inc Recent Developments
11.16 Biocep Ltd
11.16.1 Biocep Ltd Company Details
11.16.2 Biocep Ltd Business Overview
11.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Introduction
11.16.4 Biocep Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.16.5 Biocep Ltd Recent Developments
11.17 Canopus Bioscience Ltd
11.17.1 Canopus Bioscience Ltd Company Details
11.17.2 Canopus Bioscience Ltd Business Overview
11.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Introduction
11.17.4 Canopus Bioscience Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.17.5 Canopus Bioscience Ltd Recent Developments
11.18 Creatv Microtech Inc
11.18.1 Creatv Microtech Inc Company Details
11.18.2 Creatv Microtech Inc Business Overview
11.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Introduction
11.18.4 Creatv Microtech Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.18.5 Creatv Microtech Inc Recent Developments
11.19 Ikonisys Inc
11.19.1 Ikonisys Inc Company Details
11.19.2 Ikonisys Inc Business Overview
11.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Introduction
11.19.4 Ikonisys Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.19.5 Ikonisys Inc Recent Developments
11.20 IV Diagnostics Inc
11.20.1 IV Diagnostics Inc Company Details
11.20.2 IV Diagnostics Inc Business Overview
11.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Introduction
11.20.4 IV Diagnostics Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.20.5 IV Diagnostics Inc Recent Developments
11.21 Miltenyi Biotech GmbH
11.21.1 Miltenyi Biotech GmbH Company Details
11.21.2 Miltenyi Biotech GmbH Business Overview
11.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Introduction
11.21.4 Miltenyi Biotech GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.21.5 Miltenyi Biotech GmbH Recent Developments
11.22 Nanostring Technologies Inc
11.22.1 Nanostring Technologies Inc Company Details
11.22.2 Nanostring Technologies Inc Business Overview
11.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Introduction
11.22.4 Nanostring Technologies Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.22.5 Nanostring Technologies Inc Recent Developments
11.23 Rarecells Diagnostics.
11.23.1 Rarecells Diagnostics. Company Details
11.23.2 Rarecells Diagnostics. Business Overview
11.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Introduction
11.23.4 Rarecells Diagnostics. Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.23.5 Rarecells Diagnostics. Recent Developments
11.24 Vitatex Inc
11.24.1 Vitatex Inc Company Details
11.24.2 Vitatex Inc Business Overview
11.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Introduction
11.24.4 Vitatex Inc Revenue in Circulating Tumor Cell Diagnostics Business (2019-2024)
11.24.5 Vitatex Inc Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
听
听
*If Applicable.
